Actively Recruiting
Open-label Phase 1 Study Evaluating Safety and Dosage of MK-8294 in Advanced Solid Tumors
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-13
67
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying MK-8294, a targeted therapy designed to treat advanced or metastatic solid tumors such as head and neck squamous cell carcinoma, cervical squamous cell carcinoma, esophageal squamous cell carcinoma, triple-negative breast cancer, certain hormone receptor-positive breast cancers, endometrial, and bladder cancers. This Phase 1, open-label study aims to evaluate the safety, tolerance, and highest dose of MK-8294 that patients can handle. The study is sponsored by Merck Sharp & Dohme LLC and focuses on treatment for participants who have failed standard therapies or have no other options. Participants will receive MK-8294 alone through intravenous infusion at escalating doses starting from 30 micrograms up to 70 milligrams, including possible intermediate doses. The drug is administered on Days 1, 8, and 15 of each 21-day cycle, with no maximum number of cycles specified. Treatment continues until discontinuation criteria are met. Optional imaging with a CD8 PET tracer may be performed as part of the study. During the study, participants will be closely monitored for adverse events and treatment tolerance up to two years. Evaluations include blood tests measuring MK-8294 drug levels and immune responses, as well as safety assessments for dose-limiting toxicities. The study tracks objective tumor responses along with the presence of antidrug antibodies. Participants will have regular visits for treatment and assessments throughout their participation, which may last several cycles depending on individual response and tolerability.
CONDITIONS
Brief Title
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here